Skip to content

Azilsartan Medoxomil

Published: July 26, 2026Updated: August 24, 2026

Azilsartan Medoxomil is an angiotensin II receptor blocker (ARB) used to treat high blood pressure in adults. It helps relax and widen blood vessels by blocking the action of angiotensin II, a hormone that causes vessels to narrow. This medication is typically prescribed when lifestyle changes alone are insufficient to control blood pressure.

Quick summary

Azilsartan Medoxomil is an ARB medication that lowers blood pressure by blocking angiotensin II, a hormone that constricts blood vessels.

Medically reviewed by WellAlly Editorial TeamLast reviewed August 24, 2026Editorial policy

Key facts at a glance

RxNorm
1091642
Generic
Azilsartan Medoxomil
Class
pin-variant
Brands
Edarbi, Edarbyclor
Availability
rx
Lactation
unknown
Routes
—
Forms
—
Regions
US, EU, CN, JP
Monitoring
—

This page is for informational purposes only.

Do not use this information to diagnose yourself or to replace a physician's advice. Always consult a qualified healthcare provider before starting, stopping, or changing any medication. If you believe you are experiencing a medical emergency, call your local emergency number immediately.

Dosage and administration

adult (standard)tablet
Usual dose
40-80mg once daily
Maximum
consult physician
Frequency
once daily
Instructions
Follow physician instructions
Duration limits
as prescribed
Monitoring
standard
pediatric (standard)tablet
Usual dose
20-40mg once daily
Maximum
consult physician
Frequency
once daily
Instructions
Follow physician instructions
Duration limits
as prescribed
Monitoring
standard
geriatric (standard)tablet
Usual dose
40mg once daily
Maximum
consult physician
Frequency
once daily
Instructions
Follow physician instructions
Duration limits
as prescribed
Monitoring
standard

Overdose information

Important overdose information
Toxic dose: Single dose significantly exceeding therapeutic range that may cause serious toxicity
Chronic overdose: prolonged use above recommended doses may lead to cumulative hypotension and renal impairment
Immediate actions
monitor vital signs, maintain airway, intravenous fluids for blood pressure support
Antidote
no specific antidote available(treatment is supportive and symptomatic)
Poison Control: 1-800-222-1222

Special Populations

8 groups
✗

pregnancy

first trimester
unsafe
FDA Category
C
Dose Adjustment

avoid if possible

Key Recommendations

avoid use during pregnancy unless benefits outweigh risks

Monitor

regular fetal monitoring

Use of this medication in this population requires careful consideration of risks and benefits.

✗

pregnancy

second and third trimester
contraindicated
FDA Category
D
Dose Adjustment

discontinue use

Key Recommendations

do not use during second and third trimester - contraindicated due to risk of fetal renal failure and death

Monitor

discontinue immediately if pregnancy detected

Use of this medication in this population requires careful consideration of risks and benefits.

✗

lactation

breastfeeding
unsafe
FDA Category
N
Dose Adjustment

discontinue or do not use

Key Recommendations

not recommended during breastfeeding - drug excreted in breast milk

Monitor

monitor infant for hypotension

Use of this medication in this population requires careful consideration of risks and benefits.

⚠

geriatric

elderly
caution
FDA Category
N
Dose Adjustment

start at low end of dose range

Key Recommendations

initiate therapy at lower dose and monitor closely for hypotension and renal function

Monitor

monitor blood pressure and renal function regularly

Use with caution and monitor for adverse effects.

?

pediatric_age

children adolescents
unknown
FDA Category
N
Dose Adjustment

not established

Key Recommendations

not recommended for patients under 18 years due to insufficient safety and efficacy data

Monitor

not applicable

⚠

renal_impairment

severe renal impairment
caution
FDA Category
N
Dose Adjustment

use with caution, no specific dose adjustment

Key Recommendations

use with caution in patients with severe renal impairment - monitor renal function and avoid in bilateral renal artery stenosis

Monitor

monitor renal function and serum potassium regularly

Use with caution and monitor for adverse effects.

⚠

renal_impairment

moderate renal impairment
caution
FDA Category
N
Dose Adjustment

no dose adjustment required

Key Recommendations

no initial dose adjustment needed but monitor renal function

Monitor

periodic monitoring of renal function

Use with caution and monitor for adverse effects.

⚠

hepatic_impairment

hepatic impairment
caution
FDA Category
N
Dose Adjustment

no dose adjustment required

Key Recommendations

no dose adjustment needed for mild to moderate hepatic impairment - use with caution

Monitor

monitor blood pressure and liver function tests

Use with caution and monitor for adverse effects.

Statistics and clinical data

drug_classWHO
2023

Drug class

Value:Angiotensin II Receptor Blocker (ARB)

Pharmacological classification of Azilsartan Medoxomil

prescribingFDA
2023

FDA approval year

Value:2011

Regulatory approval information for Azilsartan Medoxomil

usageMedical guidelines
2023

Common therapeutic use

Value:Treatment of hypertension (high blood pressure)

Primary therapeutic indication for Azilsartan Medoxomil

mechanismFDA
2023

Mechanism of action

Value:Angiotensin II receptor antagonist

Pharmacological mechanism of action

Azilsartan Medoxomil is primarily indicated for the treatment of hypertension (high blood pressure) in adults. It may be used alone or in combination with other antihypertensive agents. Controlling high blood pressure helps prevent strokes, heart attacks, and kidney problems.

Azilsartan Medoxomil is a prodrug that is converted to its active form, azilsartan, after oral administration. It works by selectively blocking the binding of angiotensin II to the AT1 receptor in various tissues, including vascular smooth muscle and the adrenal gland. This inhibition prevents angiotensin II's vasoconstrictive and aldosterone-secreting effects, resulting in vasodilation and reduced blood pressure.

Azilsartan Medoxomil should not be used during pregnancy, particularly in the second and third trimesters, as it may cause harm to the developing fetus. Common side effects may include dizziness, diarrhea, and fatigue. Patients should avoid potassium supplements and salt substitutes containing potassium unless directed by their healthcare provider, as ARBs can increase potassium levels. This medication may interact with other drugs, including NSAIDs and lithium. Patients with a history of angioedema, renal impairment, or hepatic impairment should use this medication with caution and under medical supervision.

Contraindications

Conditions and patient states where this medication should be avoided or used with caution.

Do not use (1)

ABSOLUTEhypersensitivity

Known allergy to this medication or its components

Use caution (1)

RELATIVEpregnancy

Consult healthcare provider for benefits vs risks assessment

Official drug label

WellAlly may earn a referral fee from linked resources at no extra cost to you. Editorial content is never influenced by commercial relationships.

This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.

Medical Disclaimer

This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.

If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.

Medically reviewed by WellAlly Editorial Team Last reviewed August 24, 2026. · Read our editorial policy